Print

RV262

Phase I study of PENNVAX??G / MVA?CMDR to assess safety and immune responses in HIV?uninfected volunteers at five sites on three continents

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), U.S. Military HIV Research Program (MHRP)
MVA-CMDR,Pennvax-G Pox gag-pol CM 240, env CM235; DNA EnvA, EnvC, EnvD, Gag, and Pol
Pennvax-G DNA
MVA-CMDR Viral Vector - Pox
Kenya, Tanzania, Uganda, USA 92
NCT01260727
http://clinicaltrials.gov/ct2/show/NCT01260727?term=hiv+vaccine&lup_s=12%2F11%2F2010&lup_d=30